How Unfair Is the Coin? (ankitg.me)

Reverie Labs, a startup focused on AI-driven drug discovery, has been acquired by Ginkgo Bioworks, and its co-founder has joined Y Combinator as a Visiting Partner. This transition reflects a broader trend among AI companies in the pharmaceutical sector, as many have shifted from software sales to developing proprietary drug assets. Initially started as a machine learning software provider, Reverie evolved to create in-house drug programs, leveraging their AI capabilities to navigate complex and often counterintuitive sales dynamics within the pharmaceutical industry. The significance of Reverie's journey highlights critical lessons for AI/ML companies entering drug discovery. The firm discovered that selling software directly to pharma companies faced numerous challenges, including lengthy sales cycles and misaligned procurement incentives. As a result, Reverie pivoted to a “molecule as a service” model that allowed them to create and sell drug candidates directly, securing substantial upfront and milestone payments. However, they faced ongoing challenges, such as reliance on external contract research organizations for synthesis and difficulties in optimizing drug properties despite the advancements in AI modeling. This narrative underscores the complexities and realities of integrating AI into drug development, emphasizing the need for startups to understand the pharmaceutical landscape’s operational and economic intricacies.